查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1815807

2025年胜肽和寡核苷酸CDMO全球市场报告

Peptide And Oligonucleotide CDMO Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年胜肽和寡核苷酸CDMO市场规模将快速成长，到2029年将达到36.9亿美元，复合年增长率为11.2%。预测期内的成长可归因于个人化医疗需求的不断增长、生物技术的进步、应用的不断拓展、外包的不断增加以及慢性病负担的不断加重。预测期内的主要趋势包括个人化治疗、技术进步、品管挑战、全球扩张以及生物製药公司之间合作的加强。

未来五年11.2%的预测成长率，较我们先前对该市场的预测略有下降0.7%。这一下降主要源自于美国与其他国家之间关税的影响。贸易摩擦可能导致来自瑞士和英国的胜肽和寡核苷酸合约开发服务价格上涨，延缓生物製药开发进度，并增加治疗药物的生产成本，从而阻碍美国的生物製药创新。由于互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响，贸易摩擦的影响也将更加广泛。

胜肽和寡核苷酸 CDMO 市场有望实现成长，这得益于个人化医疗日益普及。个人化医疗可根据个人特征（如遗传、生活方式和环境）客製化医疗保健决策和治疗方案。这一趋势的驱动因素包括基因组技术的进步、对分子水平疾病机制的更深入了解，以及对根据患者基因图谱和病历定制的更有针对性和更有效的治疗方案的需求。胜肽和寡核苷酸受託製造厂商(CDMO) 透过生产根据个别患者需求量身定制的治疗胜肽和寡核苷酸，在个人化医疗中发挥关键作用。例如，2024 年 2 月，FDA 药品评估与研究中心 (CDER)核准了16 种针对罕见疾病患者的新型个人化治疗方案，比前一年显着增加。这导致个人化医疗的应用增加，推动胜肽和寡核苷酸 CDMO 市场向前发展。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球胜肽和寡核苷酸 CDMO：PESTEL 分析（政治、社会、技术、环境、法律、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球胜肽和寡核苷酸 CDMO 市场：增长率分析
  • 全球胜肽和寡核苷酸 CDMO 市场表现：规模与成长，2019-2024 年
  • 全球胜肽与寡核苷酸 CDMO 市场预测：规模与成长，2024-2029 年，2034 年
  • 全球胜肽和寡核苷酸 CDMO：总目标市场（TAM）

第六章 市场细分

  • 全球胜肽与寡核苷酸 CDMO 市场：依产品、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 胜肽
  • 寡核苷酸
  • 全球胜肽和寡核苷酸 CDMO 市场（按服务类型、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 合约开发
  • 契约製造
  • 全球胜肽与寡核苷酸 CDMO 市场：按应用、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 治疗药物
  • 调查应用
  • 诊断
  • 其他用途
  • 全球胜肽和寡核苷酸 CDMO 市场：按最终用户、实际结果和预测，2019-2024 年、2024-2029 年、2034 年
  • 生物製药公司
  • 製药公司
  • 研究机构
  • 学术和政府机构
  • 其他最终用户
  • 全球胜肽与寡核苷酸 CDMO 市场：依胜肽类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 活性药物成分（Apis）
  • 胜肽类药物
  • 胜肽合成和製造服务
  • 全球胜肽与寡核苷酸 CDMO 市场：依寡核苷酸类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 反义寡核苷酸
  • sRNA和mRNA寡核苷酸
  • 寡核苷酸合成与製造服务

第七章 区域和国家分析

  • 全球胜肽与寡核苷酸 CDMO 市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球胜肽与寡核苷酸 CDMO 市场：国家、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 胜肽和寡核苷酸 CDMO 市场：竞争格局
  • 胜肽和寡核苷酸 CDMO 市场：公司简介
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • Ajinomoto Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Lonza Group Ag Overview, Products and Services, Strategy and Financial Analysis
    • Wuxi Apptec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Catalent Inc.
  • Piramal Pharma Ltd
  • Curia Global Inc.
  • Almac Group
  • Euroapi SA.
  • CordenPharma International
  • Bachem Holding AG
  • Genscript Biotech Corporation
  • PolyPeptide Group
  • Rentschler Biopharma SE
  • Ambiopharm Inc
  • ScinoPharm
  • Senn Chemicals AG
  • Aurigene Pharmaceutical Services
  • Creative Peptides

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029 年胜肽和寡核苷酸 CDMO 市场：提供新机会的国家
  • 2029年胜肽和寡核苷酸CDMO市场：细分领域带来新机会
  • 2029年胜肽和寡核苷酸CDMO市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r30918u

A peptide and oligonucleotide CDMO (contract development and manufacturing organization) refers to a company that offers services for the development, manufacturing, and supply of peptides and oligonucleotide-based therapeutics. These organizations specialize in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to support the production of peptides and oligonucleotides for various companies.

The main product types provided by peptide and oligonucleotide CDMOs are peptides and oligonucleotides. Peptides are short chains of amino acids, typically less than 50 amino acids in length, that play crucial roles in biological processes such as signaling and hormone regulation. These CDMOs offer services including contract development and contract manufacturing. Peptides and oligonucleotides find applications in therapeutics, research applications, diagnostics, and other fields, and are utilized by end-users such as biopharmaceutical companies, pharmaceutical companies, research institutes, academic and government organizations, among others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The peptide and oligonucleotide CDMO market research report is one of a series of new reports from The Business Research Company that provides peptide and oligonucleotide CDMO market statistics, including the peptide and oligonucleotide CDMO industry global market size, regional shares, competitors with peptide and oligonucleotide CDMO market share, detailed peptide and oligonucleotide CDMO market segments, market trends, and opportunities, and any further data you may need to thrive in the peptide and oligonucleotide CDMO industry. These peptide and oligonucleotide CDMO market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peptide and oligonucleotide cdmo market size has grown rapidly in recent years. It will grow from $2.16 billion in 2024 to $2.42 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to a rise in demand for therapeutic agents, advancements in synthesis and manufacturing, personalized medicine trends, regulatory guidelines, and increased focus on antiviral peptides and mRNA vaccines highlighting the potential of oligonucleotides in vaccine development.

The peptide and oligonucleotide cdmo market size is expected to see rapid growth in the next few years. It will grow to $3.69 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to the growing demand for personalized medicine, advancements in biotechnology, expanding applications, increasing outsourcing, and the growing burden of chronic diseases. Major trends in the forecast period include personalized therapies, technological advancements, quality control challenges, global expansion, and increased collaboration among biopharmaceutical companies.

The forecast of 11.2% growth over the next five years reflects a modest reduction of 0.7% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. biopharma innovation by inflating prices of peptide and oligonucleotide contract development services sourced from Switzerland and the UK, resulting in delayed biologic drug development and raising therapeutic production costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The peptide and oligonucleotide CDMO markets are poised for growth, driven by the increasing adoption of personalized medicine. Personalized medicine tailors healthcare decisions and treatments to individual characteristics such as genetics, lifestyle, and environment. This trend is fueled by advancements in genomic technologies, deeper insights into disease mechanisms at the molecular level, and the demand for more targeted and effective treatment options customized to patients' genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a pivotal role in personalized medicine by producing customized therapeutic peptides and oligonucleotides to meet individual patient needs. For example, in February 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, a notable increase from the previous year. Consequently, the rising adoption of personalized medicine is propelling the peptide and oligonucleotide CDMO market forward.

Key players in the peptide and oligonucleotide CDMO market are forging strategic partnerships to enrich their service offerings, enhance technological capabilities, and broaden market presence. Peptide development and production partnerships entail collaborative efforts between organizations to develop and manufacture peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG teamed up with Numaferm GmbH for peptide development and production. This collaboration harnesses PolyPeptide's cGMP manufacturing capacities and market access alongside Numaferm's expertise in sustainable peptide manufacturing and biochemical production platforms. The aim is to jointly explore the development of suitable peptide candidates for more sustainable production of peptide-based APIs.

In May 2024, EUROAPI strengthened its foothold in the oligonucleotide CDMO market by acquiring BianoGMP, further enhancing its capacity in Frankfurt. BianoGMP, a Germany-based CDMO specializing in providing analytical services for oligonucleotides, augments EUROAPI's capabilities, positioning it for expanded growth and innovation in the oligonucleotide segment.

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

North America was the largest region in the peptide and oligonucleotide CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peptide and oligonucleotide cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The peptide and oligonucleotide CDMO market consists of revenues earned by entities by providing services such as analytical testing, oligonucleotide synthesis services, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide and oligonucleotide CDMO market also includes sales of custom peptides and custom oligonucleotides. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide And Oligonucleotide CDMO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide and oligonucleotide cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide and oligonucleotide cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide and oligonucleotide cdmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Peptides; Oligonucleotides
  • 2) By Service Type: Contract Development; Contract Manufacturing;
  • 3) By Application: Therapeutics; Research Applications; Diagnostics; Other Applications
  • 4) By End User: Biopharmaceutical Companies; Pharmaceutical Companies; Research Institutes; Academic and Government Organizations; Others End Users
  • Subsegments:
  • 1) By Peptides: Active Pharmaceutical Ingredients (Apis); Peptide Drug Products; Peptide Synthesis And Manufacturing Services
  • 2) By Oligonucleotides: Antisense Oligonucleotides; Sirna And Mrna Oligonucleotides; Oligonucleotide Synthesis And Manufacturing Services
  • Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Ajinomoto Co. Inc.; Lonza Group Ag; Wuxi Apptec Co. Ltd.; Catalent Inc.; Piramal Pharma Ltd; Curia Global Inc.; Almac Group; Euroapi SA.; CordenPharma International; Bachem Holding AG; Genscript Biotech Corporation; PolyPeptide Group; Rentschler Biopharma SE; Ambiopharm Inc; ScinoPharm; Senn Chemicals AG; Aurigene Pharmaceutical Services; Creative Peptides; Sylentis S.A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peptide And Oligonucleotide CDMO Market Characteristics

3. Peptide And Oligonucleotide CDMO Market Trends And Strategies

4. Peptide And Oligonucleotide CDMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Peptide And Oligonucleotide CDMO Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Peptide And Oligonucleotide CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Peptide And Oligonucleotide CDMO Market Growth Rate Analysis
  • 5.4. Global Peptide And Oligonucleotide CDMO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Peptide And Oligonucleotide CDMO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Peptide And Oligonucleotide CDMO Total Addressable Market (TAM)

6. Peptide And Oligonucleotide CDMO Market Segmentation

  • 6.1. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Peptides
  • Oligonucleotides
  • 6.2. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Contract Development
  • Contract Manufacturing
  • 6.3. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Therapeutics
  • Research Applications
  • Diagnostics
  • Other Applications
  • 6.4. Global Peptide And Oligonucleotide CDMO Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biopharmaceutical Companies
  • Pharmaceutical Companies
  • Research Institutes
  • Academic and Government Organizations
  • Others End Users
  • 6.5. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Active Pharmaceutical Ingredients (Apis)
  • Peptide Drug Products
  • Peptide Synthesis And Manufacturing Services
  • 6.6. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Oligonucleotides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antisense Oligonucleotides
  • Sirna And Mrna Oligonucleotides
  • Oligonucleotide Synthesis And Manufacturing Services

7. Peptide And Oligonucleotide CDMO Market Regional And Country Analysis

  • 7.1. Global Peptide And Oligonucleotide CDMO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Peptide And Oligonucleotide CDMO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Peptide And Oligonucleotide CDMO Market

  • 8.1. Asia-Pacific Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Peptide And Oligonucleotide CDMO Market

  • 9.1. China Peptide And Oligonucleotide CDMO Market Overview
  • 9.2. China Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Peptide And Oligonucleotide CDMO Market

  • 10.1. India Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Peptide And Oligonucleotide CDMO Market

  • 11.1. Japan Peptide And Oligonucleotide CDMO Market Overview
  • 11.2. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Peptide And Oligonucleotide CDMO Market

  • 12.1. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Peptide And Oligonucleotide CDMO Market

  • 13.1. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Peptide And Oligonucleotide CDMO Market

  • 14.1. South Korea Peptide And Oligonucleotide CDMO Market Overview
  • 14.2. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Peptide And Oligonucleotide CDMO Market

  • 15.1. Western Europe Peptide And Oligonucleotide CDMO Market Overview
  • 15.2. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Peptide And Oligonucleotide CDMO Market

  • 16.1. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Peptide And Oligonucleotide CDMO Market

  • 17.1. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Peptide And Oligonucleotide CDMO Market

  • 18.1. France Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Peptide And Oligonucleotide CDMO Market

  • 19.1. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Peptide And Oligonucleotide CDMO Market

  • 20.1. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Peptide And Oligonucleotide CDMO Market

  • 21.1. Eastern Europe Peptide And Oligonucleotide CDMO Market Overview
  • 21.2. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Peptide And Oligonucleotide CDMO Market

  • 22.1. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Peptide And Oligonucleotide CDMO Market

  • 23.1. North America Peptide And Oligonucleotide CDMO Market Overview
  • 23.2. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Peptide And Oligonucleotide CDMO Market

  • 24.1. USA Peptide And Oligonucleotide CDMO Market Overview
  • 24.2. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Peptide And Oligonucleotide CDMO Market

  • 25.1. Canada Peptide And Oligonucleotide CDMO Market Overview
  • 25.2. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Peptide And Oligonucleotide CDMO Market

  • 26.1. South America Peptide And Oligonucleotide CDMO Market Overview
  • 26.2. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Peptide And Oligonucleotide CDMO Market

  • 27.1. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Peptide And Oligonucleotide CDMO Market

  • 28.1. Middle East Peptide And Oligonucleotide CDMO Market Overview
  • 28.2. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Peptide And Oligonucleotide CDMO Market

  • 29.1. Africa Peptide And Oligonucleotide CDMO Market Overview
  • 29.2. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Peptide And Oligonucleotide CDMO Market Competitive Landscape And Company Profiles

  • 30.1. Peptide And Oligonucleotide CDMO Market Competitive Landscape
  • 30.2. Peptide And Oligonucleotide CDMO Market Company Profiles
    • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Ajinomoto Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Lonza Group Ag Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Wuxi Apptec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Peptide And Oligonucleotide CDMO Market Other Major And Innovative Companies

  • 31.1. Catalent Inc.
  • 31.2. Piramal Pharma Ltd
  • 31.3. Curia Global Inc.
  • 31.4. Almac Group
  • 31.5. Euroapi SA.
  • 31.6. CordenPharma International
  • 31.7. Bachem Holding AG
  • 31.8. Genscript Biotech Corporation
  • 31.9. PolyPeptide Group
  • 31.10. Rentschler Biopharma SE
  • 31.11. Ambiopharm Inc
  • 31.12. ScinoPharm
  • 31.13. Senn Chemicals AG
  • 31.14. Aurigene Pharmaceutical Services
  • 31.15. Creative Peptides

32. Global Peptide And Oligonucleotide CDMO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peptide And Oligonucleotide CDMO Market

34. Recent Developments In The Peptide And Oligonucleotide CDMO Market

35. Peptide And Oligonucleotide CDMO Market High Potential Countries, Segments and Strategies

  • 35.1 Peptide And Oligonucleotide CDMO Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Peptide And Oligonucleotide CDMO Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Peptide And Oligonucleotide CDMO Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer